We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Single-Agent Sequential Rx May Be Reasonable for Metastatic Breast Cancer

Jul 2, 2002
Volume: 
11
Issue: 
7
  • Breast Cancer

ORLANDO—With an ever-expanding list of active agents for metastatic
breast cancer and even more potential combinations, choosing the best
therapy for each patient can be a challenge, according to Clifford Hudis,
MD, chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering
Cancer Center. But Dr. Hudis makes a case for weighting the decision toward
single-agent sequential therapy and for keeping quality of life at the
forefront of the decision-making process.

Speaking at an industry-sponsored symposium held in conjunction with the
38th Annual Meeting of the American Society of Clinical Oncology, Dr. Hudis
prefaced his discussion with a question often asked by patients: "If we
can’t cure metastatic breast cancer, why do we treat it with chemotherapy,
with all its side effects, both large and small?"

The answer, he said, is that "we know we can palliate breast cancer.
In some cases, we can prolong survival, and that’s always remarkable when
we see it. In many cases, we can show prolonged time to progression, which
does, I believe, map to quality-of-life improvements. But quality of life
really is the bottom line."

The approach to palliation of any metastatic cancer is twofold, he said.
"You reduce tumor burden, but at the same time, you have to be very
cognizant of any negative effect on quality of life that the treatment may
cause."

With these assertions as a backdrop, Dr. Hudis reviewed the "largely
overlapping first-line activity" of commonly used agents. He suggested
that using response as the sole arbiter of benefit may not be the most
optimal approach and that the order in which these agents are applied as
first-, second-, or third-line therapy may not make a significant
difference.

Moreover, he maintained that in many instances sequential therapy can be
a better choice than combination therapy.

Dr. Hudis cited several studies of combination vs single-agent therapies
in which the combinations were slightly more active in terms of response
rate but showed no statistically significant effect on time to progression
or overall survival. Quality of life, however, was better with single-agent
regimens, he said.

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »

Related Articles

  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms
  • COUNTERPOINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
  • POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.